Regenerative Medicine is at the forefront of a revolution in healthcare, offering new hope to patients and enabling people to live longer, healthier lives. One of our latest developments is off-the-shelf, immediately available, tissue-engineered blood vessels that can potentially transform the treatment of various vascular diseases, including coronary artery diseases, peripheral arterial diseases, and arteriovenous access for hemodialysis.

Compared to traditional vascular grafts, our TEBV offers improved biocompatibility,  self-remodeling ability, and reduced risk of immune reactions. Moreover, our blood vessels can be produced in large quantities, allowing for widespread availability and immediate use in critical situations.

Roumai Medical is a cutting-edge enterprise committed to developing innovative and reliable implantable medical devices that enhance the clinical experience and extend human life expectancy. With R&D centers in China and Switzerland, we collaborate with international pharmaceutical companies to attract top talent for tackling the most challenging medical problems.

Our focus lies in addressing clinical indications such as cardiovascular and cerebrovascular diseases as well as diabetes. We have developed a range of medical devices and advanced therapeutic services with high technological barriers, including electronic blood vessels, pancreatic artificial blood vessels, brain-machine interfaces, and more.

Our electronic blood vessels mimic the natural structure and function of human blood vessels, providing a safe and reliable alternative to traditional vascular grafts. Similarly, our pancreatic artificial blood vessels have the potential to revolutionize the treatment of diabetes by regulating glucose levels through an implanted device.

In addition, our brain-machine interface technology aims to bridge the gap between humans and machines, providing new possibilities for the treatment of neurological disorders and restoring lost motor functions.